PMID- 34967503
OWN - NLM
STAT- MEDLINE
DCOM- 20220314
LR  - 20220531
IS  - 2162-3279 (Electronic)
VI  - 12
IP  - 1
DP  - 2022 Jan
TI  - Serum concentration of zinc is elevated in clinically stable bipolar disorder 
      patients.
PG  - e2472
LID - 10.1002/brb3.2472 [doi]
LID - e2472
AB  - BACKGROUND: Bipolar disorder (BD) is a chronic psychiatric disorder characterized 
      by recurrent mood episodes interspersed with euthymic periods. A growing number 
      of studies have indicated that zinc plays an important role in coordinating 
      immune responses, as well as being involved in synaptic transmission. In the 
      current study, we set out to measure serum levels of zinc in a meticulously 
      phenotyped cohort of 121 euthymic BD subjects and 30 matched controls. METHODS: 
      Serum levels of zinc were measured by photometry. To assess the interplay between 
      zinc levels and immune activation in BD, we measured serum levels of 
      high-sensitive C-reactive protein (hsCRP) levels by immunoturbidimetric assay, 
      and serum levels of monocyte chemoattractant protein-1 (MCP-1), chitinase 3-like 
      protein 1 (YKL-40), and soluble cluster of differentiation 14 (sCD14) by 
      electrochemiluminescence enzyme-linked immunosorbent assays. The baseline 
      clinical diagnostic instrument for BD was the Affective Disorder Evaluation, and 
      executive functioning was assessed by using the Delis-Kaplan Executive Function 
      System. RESULTS: Controlling for potential confounding factors, BD patients 
      displayed increased serum levels of zinc unrelated to hsCRP, MCP-1, YKL-40, and 
      sCD14 levels. Serum levels of zinc did not associate with executive functioning 
      or measurements of disease severity. DISCUSSION: This study suggests that the 
      zinc homeostasis is disturbed in BD and that this dyshomeostasis is not related 
      to ongoing mood symptoms or immune activation. Of note, serum levels were 
      increased and hence do not support continuous zinc supplementation in BD.
CI  - (c) 2021 The Authors. Brain and Behavior published by Wiley Periodicals LLC.
FAU - Jonsson, Bo H
AU  - Jonsson BH
AUID- ORCID: 0000-0002-6942-1482
AD  - Department of Clinical Neuroscience, Centre for Psychiatry Research, Stockholm & 
      Stockholm Health Care Services, Stockholm County Council, Karolinska Institutet, 
      Stockholm, Sweden.
FAU - Orhan, Funda
AU  - Orhan F
AD  - Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, 
      Sweden.
FAU - Bruno, Sanna
AU  - Bruno S
AD  - Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, 
      Sweden.
FAU - Oliveira, Ana Osorio
AU  - Oliveira AO
AD  - Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, 
      Sweden.
FAU - Sparding, Timea
AU  - Sparding T
AD  - Section of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University 
      of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden.
FAU - Landen, Mikael
AU  - Landen M
AD  - Section of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University 
      of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden.
AD  - Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, 
      Stockholm, Sweden.
FAU - Sellgren, Carl M
AU  - Sellgren CM
AD  - Department of Clinical Neuroscience, Centre for Psychiatry Research, Stockholm & 
      Stockholm Health Care Services, Stockholm County Council, Karolinska Institutet, 
      Stockholm, Sweden.
AD  - Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, 
      Sweden.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20211230
PL  - United States
TA  - Brain Behav
JT  - Brain and behavior
JID - 101570837
RN  - 9007-41-4 (C-Reactive Protein)
RN  - J41CSQ7QDS (Zinc)
SB  - IM
MH  - Affect
MH  - *Bipolar Disorder/metabolism
MH  - C-Reactive Protein
MH  - Executive Function
MH  - Humans
MH  - *Zinc/blood/metabolism
PMC - PMC8785612
OTO - NOTNLM
OT  - C-reactive protein
OT  - bipolar patients
OT  - cognition
OT  - serum
OT  - zinc
COIS- Carl M. Sellgren is a scientific adviser for Outermost Therapeutics (of no 
      relevance to this work). The authors have no financial conflicts of interest.
EDAT- 2021/12/31 06:00
MHDA- 2022/03/15 06:00
PMCR- 2021/12/30
CRDT- 2021/12/30 08:47
PHST- 2021/11/06 00:00 [revised]
PHST- 2021/07/04 00:00 [received]
PHST- 2021/12/01 00:00 [accepted]
PHST- 2021/12/31 06:00 [pubmed]
PHST- 2022/03/15 06:00 [medline]
PHST- 2021/12/30 08:47 [entrez]
PHST- 2021/12/30 00:00 [pmc-release]
AID - BRB32472 [pii]
AID - 10.1002/brb3.2472 [doi]
PST - ppublish
SO  - Brain Behav. 2022 Jan;12(1):e2472. doi: 10.1002/brb3.2472. Epub 2021 Dec 30.